VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial

Robin Kate Kelley, Thomas Yau, Ann‐Lii Cheng, Ahmed O. Kaseb, Shukui Qin, Andrew X. Zhu, Stephen L. Chan, Wattana Sukeepaisarnjaroen, В. В. Бредер, Gontran Verset, Edward Gane, Ivan Borbath, J.D. Gomez Rangel, Philippe Merle, Fawzi Benzaghou, Kamalika Banerjee, Saswati Hazra, Jonathan W. Fawcett, Lorenza Rimassa